PathAI, Discovery Life Sciences Partner on AI-Powered Biospecimen Solutions

PathAI, a leader in AI-powered pathology technology, has announced a strategic partnership with Discovery Life Sciences, a top biospecimen and specialty lab testing provider. This collaboration will offer Discovery’s customers AI-enabled digital and quantitative insights from biospecimens to enhance drug and diagnostic development. It marks the first large-scale deployment of AI in a major commercial biobank.

Discovery will integrate PathAI’s AISight® Image Management System (IMS), ArtifactDetect, and TumorDetect products globally into its biospecimen business. This will streamline pathology workflows by automating routine tasks, saving pathologists time, and providing additional tissue-level insights for more accurate and standardized data.

The partnership will also focus on creating a custom AI-driven tissue analysis panel to support translational research and biomarker discovery for biopharma. Beyond biospecimens, the partnership may expand into Discovery’s Specialty Lab Services to further accelerate drug development and precision medicine.

Andy Beck, CEO of PathAI, expressed excitement about revolutionizing the biospecimens industry with their digital pathology solutions, improving accuracy and accelerating the development of new therapies and diagnostics. Greg Herrema, CEO of Discovery, highlighted how integrating PathAI’s AI technology will improve the quality and timeliness of data and insights, advancing the discovery of therapies that enhance patient outcomes.

With rising investments in immuno-oncology and antibody-drug conjugates, the collaboration will optimize diagnostic tools and patient selection, advancing the development of new assays and improving patient outcomes.